Pieris Pharmaceuticals, INC Schedule 13G passive stakes

Prudential Financial, Inc. has filed a Schedule 13G, reporting a 6.7% beneficial ownership in Palvella Therapeutics, Inc.

Jennison Associates LLC has reported beneficial ownership of 960,619 shares, representing 6.7% of Palvella Therapeutics Inc.'s common stock, as of June 30, 2026.

Frazier Life Sciences funds updated their beneficial ownership in Palvella Therapeutics, Inc., reporting a 6.0% stake for its Public Fund.

Biotechnology Value Fund and its affiliates have disclosed a combined beneficial ownership of 9.99% in Palvella Therapeutics, Inc., including shares from pre-funded warrants.

Suvretta Capital Management, LLC and Averill Master Fund, Ltd. updated their beneficial ownership in Palvella Therapeutics, Inc., reporting 7.4% and 6.5% stakes respectively.

Samsara BioCapital, L.P. and its affiliates reported a reduced beneficial ownership of 3.1% in Palvella Therapeutics, Inc. common stock as of June 30, 2025.

Frazier Life Sciences funds updated their beneficial ownership in Palvella Therapeutics, Inc., collectively holding approximately 6.5% of common stock.

Frazier Life Sciences Public Fund and its affiliated entities, along with key individuals, have filed an amended Schedule 13G/A disclosing their passive beneficial ownership in Palvella Therapeutics, Inc., with certain individuals holding over 6% of the common stock.

A group of Frazier Life Sciences funds and their principals have filed a Schedule 13G, disclosing beneficial ownership of 5.1% of Palvella Therapeutics, Inc.'s Common Stock as of December 13, 2024.